Diabetic Peripheral Neuropathy Associated with Cardiovascular Risk Factors and Glucagon-Like Peptide-1 Concentrations Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus

References

• Yovera-Aldana M, Velásquez-Rimachi V, Huerta-Rosario A, et al. Prevalence and incidence of diabetic peripheral neuropathy in Latin America and the Caribbean: a systematic review and meta-analysis. PLoS One. 2021;16:e0251642. doi:10.1371/journal.pone.0251642
   Web of Science ®Google Scholar
• Wani FA, Koul RK, Raina AA, et al.Prevalence of microvascular complications in newly diagnosed type 2 diabetes patients. Int J Curr Res. 2018;10:67231–67233.
   Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817. doi:10.1212/WNL.43.4.817
   PubMed Web of Science ®Google Scholar
• Abdollahi A. Neuropathy and retinopathy in diabetes: is there any association? Int J Ophthalmol. 2009;2:57–60.
   Web of Science ®Google Scholar
• Sothornwit J, Srisawasdi G, Suwannakin A, Sriwijitkamol A. Decreased health-related quality of life in patients with diabetic foot problems. Diabetes Metab Syndr Obes Targets Ther. 2018;11:35.
   PubMed Web of Science ®Google Scholar
• Ni W, Zhang Z, Zhang B, et al. Connecting peripheral to central neuropathy: examination of nerve conduction combined with olfactory tests in patients with type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2021;14:3097–3107. doi:10.2147/DMSO.S312021
   Web of Science ®Google Scholar
• Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and UK. Prim Care Diabetes. 2014;8:250–255. doi:10.1016/j.pcd.2014.01.011
   PubMed Web of Science ®Google Scholar
• Ko S-H, Cha B-Y. Diabetic peripheral neuropathy in type 2 diabetes mellitus in Korea. Diabetes Metab J. 2012;36:6. doi:10.4093/dmj.2012.36.1.6
   Google Scholar
• Román-Pintos LM, Villegas-Rivera G, Rodríguez-Carrizalez AD, Miranda-Díaz AG, Cardona-Muñoz EG. Diabetic polyneuropathy in type 2 diabetes mellitus: inflammation, oxidative stress, and mitochondrial function. J Diabetes Res. 2016;2016:1–16. doi:10.1155/2016/3425617
   Web of Science ®Google Scholar
• Reiber Ge LJ. Epidemiology and Economic impact of foot ulcers and amputations in people with diabetes. In: Bowker JH, Pfeifer MA, editors. Levin and O’Neal’s the Diabetic Foot. Philadelphia, Mosby: Elsevier; 2008:3–32.
   Google Scholar
• Fiorentino T, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19:5695–5703.
   PubMed Web of Science ®Google Scholar
• Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol. 2014;2014:1–10. doi:10.1155/2014/674987
   Web of Science ®Google Scholar
• Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Prim. 2019;5:41. doi:10.1038/s41572-019-0092-1
   PubMed Web of Science ®Google Scholar
• Han L, Ji L, Chang J, et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol Metab Syndr. 2015;7:14. doi:10.1186/s13098-015-0010-y
   Web of Science ®Google Scholar
• Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017;40:257–262. doi:10.1016/j.bj.2017.06.007
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300:958–966.
   PubMed Web of Science ®Google Scholar
• Kan M, Guo G, Singh B, Singh V, Zochodne DW. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol. 2012;71:494–510. doi:10.1097/NEN.0b013e3182580673
   PubMed Web of Science ®Google Scholar
• During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173–1179. doi:10.1038/nm919
   PubMed Web of Science ®Google Scholar
• Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302:881–888. doi:10.1124/jpet.102.037481
   PubMed Web of Science ®Google Scholar
• Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203:293–301. doi:10.1016/j.expneurol.2006.09.028
   PubMed Web of Science ®Google Scholar
• Daisuke YS, Yabe D. Glucose - dependent insulinotropic polypeptide and glucagon - like peptide −1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4:108–1130. doi:10.1111/jdi.12065
   Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 2010;391:1405–1408. doi:10.1016/j.bbrc.2009.12.075
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2019 abridged for primary care providers. Clin Diabetes. 2019;37:11–34. doi:10.2337/cd18-0105
   PubMedGoogle Scholar
• Nascimento OJM, Do Pupe CCB, Cavalcanti EBU. Diabetic neuropathy. Rev Dor. 2016;17. doi:10.5935/1806-0013.20160047
   Google Scholar
• Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154. doi:10.1007/BF00400697
   PubMed Web of Science ®Google Scholar
• Rubino A, Rousculp MD, Davis K, et al. Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes. 2007;1:129–134. doi:10.1016/j.pcd.2007.07.006
   Google Scholar
• Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19:86. doi:10.1007/s11892-019-1212-8
   PubMed Web of Science ®Google Scholar
• Malik RA, Andag‐Silva A, Dejthevaporn C, et al. Diagnosing peripheral neuropathy in South‐East Asia: a focus on diabetic neuropathy. J Diabetes Investig. 2020;11:1097–1103. doi:10.1111/jdi.13269
   PubMed Web of Science ®Google Scholar
• Pan Q, Li Q, Deng W, et al. Prevalence of and risk factors for peripheral neuropathy in Chinese patients with diabetes: a multicenter cross-sectional study. Front Endocrinol (Lausanne). 2018;9. doi:10.3389/fendo.2018.00617
   Web of Science ®Google Scholar
• Thy Khue N. Diabetes in Vietnam. Ann Glob Health. 2016;81:870. doi:10.1016/j.aogh.2016.01.003
   Web of Science ®Google Scholar
• Nguyen CT, Pham NM, Tran DV, Lee AH, Binns CW. Lifestyle and diet in relation to risk of type 2 diabetes in Vietnam: a hospital-based case–control study. Springerplus. 2016;5:687. doi:10.1186/s40064-016-2313-3
   Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SEM, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–350. doi:10.1056/NEJMoa032782
   PubMed Web of Science ®Google Scholar
• Yang C-P, Lin -C-C, Li C-I, et al. Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Medicine (Baltimore). 2015;94:e1783. doi:10.1097/MD.0000000000001783
   Web of Science ®Google Scholar
• Mao F, Zhu X, Liu S, et al. Age as an independent risk factor for diabetic peripheral neuropathy in Chinese patients with type 2 diabetes. Aging Dis. 2019;10:592. doi:10.14336/AD.2018.0618
   Web of Science ®Google Scholar
• Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep. 2013;13:805–813. doi:10.1007/s11892-013-0425-5
   PubMed Web of Science ®Google Scholar
• Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med. 2015;30:1193–1203. doi:10.1007/s11606-015-3354-y
   PubMed Web of Science ®Google Scholar
• Mitchell BD, Hawthorne VM, Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care. 1990;13:434–437. doi:10.2337/diacare.13.4.434
   PubMed Web of Science ®Google Scholar
• Ristikj-Stomnaroska D, Risteska-Nejashmikj V, Papazova M. Role of inflammation in the pathogenesis of diabetic peripheral neuropathy. Open Access Maced J Med Sci. 2019;7:2267–2270. doi:10.3889/oamjms.2019.646
   Google Scholar
• Mussa BM, Srivastava A, Al-Habshi A, et al. Inflammatory biomarkers levels in T2DM Emirati patients with diabetic neuropathy. Diabetes Metab Syndr Obes Targets Ther. 2021;14:3389–3397. doi:10.2147/DMSO.S319863
   PubMed Web of Science ®Google Scholar
• Brownrigg JRW, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart. 2014;100:1837–1843. doi:10.1136/heartjnl-2014-305657
   Web of Science ®Google Scholar
• Ali A, Iqbal F, Taj A, et al. Prevalence of microvascular complications in newly diagnosed patients with type 2 diabetes. Pak J Med Sci. 2013;29:899.
   PubMed Web of Science ®Google Scholar
• Xu L, Lin X, Guan M, Liu Y. Correlation between different stages of diabetic nephropathy and neuropathy in patients with T2DM: a cross-sectional controlled study. Diabetes Ther. 2018;9:2335–2346. doi:10.1007/s13300-018-0519-9
   Web of Science ®Google Scholar
• Zhang Y, Jiang Y, Shen X, Yan S. Can both normal and mildly abnormal albuminuria and glomerular filtration rate be a danger signal for diabetic peripheral neuropathy in type 2 diabetes mellitus? NeurolSci. 2017;38:1381–1390.
   Google Scholar
• Aleidan FA, Ahmad BA, Alotaibi FA, et al. Prevalence and risk factors for diabetic peripheral neuropathy among Saudi hospitalized diabetic patients: a nested case-control study. Int J Gen Med. 2020;13:881–889.
   Web of Science ®Google Scholar
• Zhong M, Yang Y-R, Zhang Y-Z, Yan S-J. Change in urine albumin-to-creatinine ratio and risk of diabetic peripheral neuropathy in type 2 diabetes: a retrospective cohort study. Diabetes Metab Syndr Obes Targets Ther. 2021;14:1763–1772.
   Web of Science ®Google Scholar
• Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.
   PubMed Web of Science ®Google Scholar
• León DD, De Crutchlow MF, Ham J-YN, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol. 2006;38:845–859. doi:10.1016/j.biocel.2005.07.011
   Web of Science ®Google Scholar
• Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357–366. doi:10.1007/s00125-004-1342-6
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Metab. 2004;287:E199–E206.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab. 2009;11:11–18. doi:10.1111/j.1463-1326.2009.01073.x
   PubMed Web of Science ®Google Scholar
• Alonso N, Julián MT, Puig-Domingo M, Vives-Pi M. Incretin hormones as immunomodulators of atherosclerosis. Front Endocrinol (Lausanne). 2012;3. doi:10.3389/fendo.2012.00112
   Google Scholar
• Sheikh A. Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr. 2013;5:47. doi:10.1186/1758-5996-5-47
   PubMed Web of Science ®Google Scholar
• Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun. 2012;425:304–308. doi:10.1016/j.bbrc.2012.07.086
   PubMed Web of Science ®Google Scholar
• Ceriello A, Novials A, Ortega E, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013;36:2346–2350. doi:10.2337/dc12-2469
   PubMed Web of Science ®Google Scholar
• Chapouly C, Yao Q, Vandierdonck S, et al. Impaired Hedgehog signalling-induced endothelial dysfunction is sufficient to induce neuropathy: implication in diabetes. Cardiovasc Res. 2016;109:217–227. doi:10.1093/cvr/cvv263
   Web of Science ®Google Scholar
• Shirazi RH, Dickson SL, Skibicka KP, Caramelli D. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS One. 2013;8:e61965. doi:10.1371/journal.pone.0061965
   PubMed Web of Science ®Google Scholar
• Jerlhag E. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology. 2018;136:343–349. doi:10.1016/j.neuropharm.2018.01.013
   PubMed Web of Science ®Google Scholar
• Yan P, Tang Q, Wu Y, et al. Serum albumin was negatively associated with diabetic peripheral neuropathy in Chinese population: a cross-sectional study. Diabetol Metab Syndr. 2021;13:100. doi:10.1186/s13098-021-00718-4
   Web of Science ®Google Scholar
• Wiggin TD, Sullivan KA, Pop-Busui R, et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58:1634–1640. doi:10.2337/db08-1771
   PubMed Web of Science ®Google Scholar
• Ponirakis G, Petropoulos IN, Alam U, et al. Hypertension contributes to neuropathy in patients with type 1 diabetes. Am J Hypertens. 2019;32:796–803. doi:10.1093/ajh/hpz058
   Web of Science ®Google Scholar